Core Viewpoint - Macquarie has upgraded Alibaba Health (00241) from "Underperform" to "Outperform" and raised its adjusted net profit forecasts for fiscal years 2026 and 2027 by 6% and 20% respectively, reflecting improved profitability due to market consolidation [1] Group 1: Company Analysis - The target price for Alibaba Health has been increased from HKD 3.4 to HKD 6.78 [1] - The online healthcare industry is believed to have structurally improved, with market share accelerating from offline channels [1] - Encouragement is noted regarding leading pharmaceutical companies adopting online channels to launch new drugs and specialty medications [1] Group 2: Industry Insights - The integration of Alibaba's 88VIP program is expected to bring additional traffic synergy benefits [1]